VP-16 and adriamycin in patients with advanced breast cancer.

Abstract

Twenty-eight patients with advanced adenocarcinoma of the breast were treated with a combination of VP-16 and adriamycin (VAD). Two complete (CR), and eight partial (PR) remissions were observed. The CR plus PR produced a 36% response rate in this study. Nine additional patients had stable disease for at least 2 months. No drug deaths were seen with this combination, but thrombocytopenia, leukopenia, and vomiting were observed. Alopecia was seen in 100% of the patients treated with the above combination. This study suggests that the combination of adriamycin and VP-16 may be a good second-line therapy for patients with adenocarcinoma of the breast who failed and/or relapsed to CMFVP.

• Authors: C B Vaughn, E Maniscalco-Greb, C Lockhard, G Groshko, K Enochs, H Duffin, M Demitrish
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 5 Issue 5 Pg. 505-9 (Oct 1982) ISSN: 0277-3732 [Print] United States
• PMID: 6897491 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Vincristine
• Etoposide
• Dexamethasone
• Doxorubicin
• Cyclophosphamide
• Podophyllotoxin
• Fluorouracil
• Prednisone
• Methotrexate

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Aged
• Alopecia (chemically induced)
• Antineoplastic Combined Chemotherapy Protocols
• Breast Neoplasms (drug therapy)
• Cyclophosphamide (administration & dosage)
• Dexamethasone
• Doxorubicin (administration & dosage, adverse effects)
• Drug Therapy, Combination
• Etoposide (administration & dosage, adverse effects)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Leukopenia (chemically induced)
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Podophyllotoxin (analogs & derivatives)
• Prednisone (administration & dosage)
• Thrombocytopenia (chemically induced)
• Vincristine (administration & dosage)
• Vomiting (chemically induced)